SCHEMBL5833211

SCHEMBL5833211

COc1ccc(CN(C)C(Cc2ccncc2)C(=O)NC(Cc2ccc(OCc3ccccc3)cc2)C(=O)NC(C)(C)C)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.46
PKM P14618 1/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MAOB P27338 3/20 0.46
MME P08473 1/20 0.45
ACE P12821 1/20 0.45
CPA1 P15085 1/20 0.45
ACE2 Q9BYF1 1/20 0.45
MMP9 P14780 2/20 0.44
MMP8 P22894 1/20 0.44
SLC2A1 P11166 4/20 0.44
MMP1 P03956 1/20 0.43
MMP3 P08254 1/20 0.43
GPR132 Q9UNW8 2/20 0.43
SLC2A4 P14672 1/20 0.43
HDAC8 Q9BY41 1/20 0.42
OPRM1 P35372 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5833373 0.93 GPR132 (0.49) ALDH1A1GAAMAPTPKMHTT
SCHEMBL5833224 0.93 MAOB (0.45) ALDH1A1MAPTMAOBMMEACE
SCHEMBL7408957 0.90 MAOB (0.48) MAOBMMEACECPA1ACE2
SCHEMBL7370362 0.88 REN (0.49) MAOBMMEACECPA1ACE2
SCHEMBL5832609 0.88 MAOB (0.49) MAOBMMEACECPA1ACE2
SCHEMBL5832618 0.88 MAOB (0.46) MAOBMMEACECPA1ACE2
SCHEMBL5833257 0.87 MMP9 (0.44) MAOBMMEACECPA1ACE2
SCHEMBL5833093 0.87 MAOB (0.48) MAOBMMEACECPA1ACE2
SCHEMBL5833078 0.86 GPR132 (0.49) GAAMMEACECPA1ACE2
SCHEMBL7375477 0.85 MME (0.52) MAOBMMEACECPA1ACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030060419-A1 Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers HU LAIN-YEN (US) 2003-03-27 US claimed
US-6166052-A Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers WARNER-LAMBERT COMPANY (US) 2000-12-26 US claimed
US-6989448-B2 Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers HU LAIN-YEN 2006-01-24 US disclosed
US-20030060419-A1 Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers HU LAIN-YEN (US) 2003-03-27 US disclosed
US-6469038-B1 CALCIUM CHANNEL BLOCKERS THAT CAN BLOCK N-TYPE CALCIUM CHANNELS AND CAN BE USED TO TREAT STROKE, PAIN, CEREBRAL ISCHEMIA, HEAD TRAUMA, ASTHMA, AMYOTROPIC LATERAL SCLEROSIS, AND EPILEPSY WARNER-LAMBERT COMPANY 2002-10-22 US disclosed
US-6166052-A Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers WARNER-LAMBERT COMPANY (US) 2000-12-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030060419-A1 Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers CACNA1C, CACNA1I, CACNA1S ALDH1A1 3661/4885GAA 2209/4885MAPT 2036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.